1. Home
  2. SG vs TECX Comparison

SG vs TECX Comparison

Compare SG & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sweetgreen Inc.

SG

Sweetgreen Inc.

HOLD

Current Price

$8.97

Market Cap

640.3M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.02

Market Cap

549.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SG
TECX
Founded
2007
2019
Country
United States
United States
Employees
N/A
60
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
549.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SG
TECX
Price
$8.97
$30.02
Analyst Decision
Hold
Strong Buy
Analyst Count
15
5
Target Price
$8.43
$75.20
AVG Volume (30 Days)
5.7M
132.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.05
N/A
Revenue
$679,474,000.00
N/A
Revenue This Year
$7.60
N/A
Revenue Next Year
$8.45
N/A
P/E Ratio
$8.52
N/A
Revenue Growth
0.39
N/A
52 Week Low
$4.49
$14.39
52 Week High
$16.70
$35.99

Technical Indicators

Market Signals
Indicator
SG
TECX
Relative Strength Index (RSI) 56.54 54.28
Support Level $6.39 $27.31
Resistance Level $9.14 $31.39
Average True Range (ATR) 0.75 1.89
MACD -0.02 0.12
Stochastic Oscillator 57.24 71.39

Price Performance

Historical Comparison
SG
TECX

About SG Sweetgreen Inc.

Sweetgreen Inc is a mission-driven, next-generation restaurant and lifestyle brand that serves healthy food at scale. Its bold vision is to be as ubiquitous as traditional fast food, but with the transparency and quality that consumers increasingly expect. It is creating plant-forward, seasonal, and earth-friendly meals from fresh ingredients and produce that prioritizes organic, regenerative, and local sourcing. Its menu involves, Kids' meal, salads, sides, local items, Protein Plates, Desserts, Drinks and Others.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: